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Introduction: Given the growing burden of venous thromboembolism (VTE) worldwide and the paucity of
data from the developing world, the aim of this study was to audit the characteristics, risk factors and
length of hospital stay of patients with VTE presenting to a tertiary hospital emergency centre in
Johannesburg, South Africa.
Methods: The study was a retrospective record review of all patients who presented with VTE to a tertiary
academic emergency centre in Johannesburg, South Africa from 1 April 2012 to 30 March 2013.
Results: Venous thromboembolism was identified in 74 patients; 56 (75.7%) with isolated deep vein
thrombosis, 13 (17.6%) with pulmonary embolism and five (6.8%) who had a concurrent deep vein throm-
bosis with pulmonary embolism. The median age of the patients was 40 years old (range 19–90). The
female to male ratio was 2:1. HIV infection, tuberculosis and history of immobilisation were the most
common risk factors. The median duration of hospital stay was 14 days (range 4–36). A therapeutic
International Normalised Ratio at discharge was only reached in 36.5% of patients.
Conclusion: Venous thromboembolism presentation to the emergency centre is not common, but the
risks associated with the morbidity and mortality related to it makes it important despite its relative scar-
city. The prevalence of HIV infection amongst patients with VTE is concerning – not only related to the
frequency of the pathology but also due to HIV not being factored into the common VTE risk stratification
scores.
 2017 African Federation for Emergency Medicine. Publishing services provided by Elsevier B.V. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).African Relevance
 Despite the risks, there is a paucity of venous thromboembolism
data in developing countries.
 HIV prevalence is high; HIV infection is not a factor included in
the common venous thromboembolism scoring systems.
 Venous thromboembolism guideline changes make outpatient
management an option for resource-limited environments.
Introduction
The presentation of patients with venous thromboembolism
(VTE), ranging from asymptomatic deep vein thrombosis (DVT) to
fatal pulmonary embolism (PE), is commonplace in emergency
centres in high-income countries [1,2]. It is also a common causeof morbidity and mortality [3]. However, little data exist regarding
the incidence and management of VTE in low- and middle-income
countries (LMICs) [4,5].
Some of the conventional risk factors for VTE include increasing
age, cancer, obesity, smoking, surgery, immobilisation and hor-
mone therapy [3]. Despite initial controversy, Human Immunode-
ficiency Virus (HIV) infection is now acknowledged as an
independent risk factor for VTE [3,6]. Due to the higher prevalence
of HIV infection in LMICs, particularly in sub-Saharan Africa,
patients who present with VTE may have very different character-
istics than patients who present with VTE in high-income countries
[7].
Given the growing burden of VTE worldwide and the paucity of
data from LMICs, the aim of this study was to audit the character-
istics, risk factors and length of hospital stay of patients with VTE
presenting to a tertiary hospital emergency centre.
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This study was a retrospective record review of all patients who
presented with VTE to a tertiary academic emergency centre in
Johannesburg, South Africa from 1 April 2012 to 30 March 2013.
The emergency centre has approximately 60,000 patient visits
per annum. This research was approved by the Human Research
Ethics Committee of the Faculty of Health Sciences of the Univer-
sity of the Witwatersrand [M130607].
Patients presenting with VTE were identified through the emer-
gency centre registers as well as the radiology department records
of DVT ultrasound and computed tomography pulmonary angio-
grams for PE. The files of these patients were then retrieved from
the records department and the data captured by a single abstrac-
tor according to a structured data collection sheet. Common VTE
risk factors (Table 1) were sought within the patient files. As the
study was an audit, the abstractor was not blinded to the out-
comes. Any conflicting data were discussed and clarified with an
emergency physician.
Patients were only included if they had presented to the emer-
gency centre with a complaint that lead to a diagnosis of PE or DVT
(i.e. hospital-acquired VTE was not included). Patients were
included even if the diagnosis was not made or suspected in the
emergency centre.
Patients that were admitted with VTE were given subcutaneous
low molecular weight heparin (enoxaparin) and then bridged to
oral warfarin.Results
Venous thromboembolism was identified in 74 patients; 56
(75.7%) with isolated DVT and 13 (17.6%) with isolated PE. There
were five (6.8%) patients who had a concurrent DVT with PE.
The median age of the patients with VTE was 40 years (range
19–90). Thirty-five patients (47.3%) were below the age of 40 years
(Fig. 1). There was no statistically significant difference between
the median age of patients with DVT (39 years; range 23–90) com-
pared to the median age of patients with PE (44 years old; range
19–73). 74% of the patients with VTE were Black, 15% Coloured
and 11% Caucasian. The female to male ratio was 2:1. Venous
thromboembolism risk factors that were identified from the
patients’ files are summarised in Table 1.
There were 30 HIV positive patients below the age of 50 years
(85.7% of all HIV positive patients). Twenty-four (68.6%) of the
HIV positive patients were taking highly active antiretroviral ther-
apy. Fig. 1 shows the distribution of HIV infection per age group.Table 1
Venous thromboembolism risk factors, N = 70*, **.
VTE Risk Factors Number of patients (%)
HIV Positive 35 (50.0)
Tuberculosis 21 (30.0)
Immobilisation 17 (24.3)
Smoking 11 (15.7)
Active Cancer 7 (10.0)
Post-Partum 6 (8.6)
Recent Surgery 5 (7.1)
Trauma 5 (7.1)
Central venous catheter in affected limb 3 (4.3)
Obesity*** 3 (4.3)
Previous history of VTE 3 (4.3)
Systemic Lupus Erythematous 2 (2.9)
VTE, venous thromboembolism; HIV, human immunodeficiency virus; *, four
patients were excluded due to lack of documentation; **, patients may have had
more than one risk factor; ***, not always documented in the file.The median duration of hospital stay was 14 days (range 4–36).
Hospital length of stay is shown in Fig. 2.
A therapeutic International Normalised Ratio (INR) at discharge
was reached in 36.5% (n = 27) of patients, while a therapeutic INR
was not reached in 18 (24.3%) patients; follow-up was arranged
for a repeat INR in the latter group. The INR at discharge was not
documented in 29 (39.2%) patients.Discussion
Whilst only 1:1000 patients who presented to the emergency
centre had VTE, the significance of the potential morbidity and
mortality associated with this condition outweighs its relative
scarcity. This is marginally higher than rates reported in the liter-
ature of 67–80 per 100,000 people [2].
Similar to previous studies, DVT was unsurprisingly more com-
mon than PE [1]. Although increasing age is known to be a risk fac-
tor for VTE, the median age of our population was 40 years, which
is the same as that found by Awolesi et al. at an urban district hos-
pital in KwaZulu-Natal, South Africa [8]. The younger age of these
patients is most likely related to the higher rate of HIV infection in
this age group (Fig. 1). HIV infection was the most commonly asso-
ciated risk factor for VTE, followed by tuberculosis. Some of the
patients with HIV had co-infection with tuberculosis. This may
have contributed to VTE in itself but also may have been potenti-
ated by the immobility secondary to chronic illness, further predis-
posing them to VTE. Although male gender is known to be a risk
factor, as with Awolesi et al.’s cohort, there was also a female pre-
ponderance in our study [8,9].
More than half of the HIV infected patients were taking highly
active antiretroviral therapy. The therapy itself is an independent
risk factor for VTE [6]. This, as well as the high prevalence of HIV
in South Africa, underscores our concerns about the exclusion of
these risk factors in the major VTE scoring systems, such as the
Modified Wells Scoring System, the Revised Geneva Scoring Sys-
tem and the Pulmonary Embolism Rule Out Criteria score [10–
12]. These scoring systems were not utilised in this study’s emer-
gency centre when the data from this study were collected. How-
ever, these scoring systems are frequently used in the South
African clinical setting despite lack of validation in our population.
The modifiable risk factors of smoking and obesity could possi-
bly have been underestimated due to lack of documentation in the
patient files. Cheng et al., however, emphasised both of their asso-
ciations with VTE in their 2013 meta-analysis [13].
As was the procedure in our hospital, the traditional manage-
ment of patients with VTE requires hospital admission in order
for patients to be started on parenteral heparin (either low molec-
ular weight or unfractionated) and then be bridged to an oral vita-
min K antagonist (e.g. warfarin) [1]. Patients are usually kept in
hospital until their INR is within the therapeutic range, which
may take several days [14]. This is echoed in the 2013 Southern
African Society of Thrombosis and Haemostasis guidelines [15].
This model led to a median length of stay of two weeks for our
patients. Even with this protracted admission, only 36.5% of
patients were discharged with an INR in the therapeutic range,
and even though a therapeutic INR was obtained, the time in the
therapeutic range for warfarin is commonly only 60–68% [16,17].
But there are also costs (monetary and health-related) linked to
hospital admission that need to be taken into account. Although
data were not collected regarding morbidity related to admission,
it is known that hospital admission itself is not without negative
sequelae such as nosocomial pneumonia, urinary tract infections
and bedsores.
The 2013 Southern African Society of Thrombosis and Hae-
mostasis guidelines were released prior to the registration of the
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Fig. 1. HIV prevalence amongst the patients presenting with VTE by age group. VTE, venous thromboembolism; HIV, Human Immunodeficiency Virus.
Fig. 2. Duration of hospital stay in patients with VTE* (median with inter-quartile
ranges). DVT, deep vein thrombosis; PE, pulmonary embolism; *, Data available for
58 patients.
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The advent of NOACs, such as dabigatran, rivaroxaban, apixaban
and edoxaban has challenged the treatment paradigm. The 2016
American College of Chest Physicians guidelines now recommend
the use of NOACs over vitamin K antagonists as primary therapy
[18]. There is also increasing evidence to support outpatient man-
agement and direct discharge from the emergency centre for low-
risk patients with DVT and/or PE [1,18,19]. The largest of these tri-
als will be completed in August 2017 in the United States [20].
Kline et al. showed that patients preferred the autonomy asso-
ciated with outpatient management [21]. This may also have a
knock-on effect leading to better patient compliance. The ramifica-
tions of VTE admission, continued INR monitoring and higher inci-
dence of severe bleeding complications needs to be balanced
against the higher costs of utilising the newer, safer NOACs for out-
patient treatment. Perhaps all these factors combined are sufficient
to justify outpatient management of VTE in South Africa? If feasible
and economically viable, this could potentially be beneficial for the
outpatient management of VTE from the emergency centre in
LMICs. Further cost-benefit and outcome-related prospective stud-
ies would better answer this question.
These data were collected from 2012 to 2013 prior to the imple-
mentation of VTE protocols in the emergency centre. The retro-
spective nature of this audit made missing data a constraint for
analysis, e.g. not all patients may have been asked about all possi-ble risk factors. This was a single centre study making wider appli-
cability limited. Without the benefit of electronic health records or
a registry to obtain the data, some VTE patients may have been
inadvertently excluded. Data regarding morbidity and mortality
were not collected.
Venous thromboembolism presentation to the emergency cen-
tre is not common, but the risks associated with the morbidity
and mortality related to it makes it important despite its relative
scarcity. The prevalence of HIV infection amongst patients with
VTE is concerning, not only related to the frequency of the pathol-
ogy but also due to HIV not being factored into the common VTE
risk stratification scores.Conflicts of interest
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